The former allowed a complete inhibition of experimentally induced arthritis with a decreased TNF-α secretion by 50–70% [112]; the latter delayed RA onset and progression through the inhibition of joint swelling and bone destruction for siRNA of all interleukins used individually. The gene discussed is TNF; the disease is arthritic joint disease.